NorthWest Biotherapeutics Inc (NWBO)

[ae kusterer]

ATNTFTP:



ATLnsider Wednesday, 03/09/22 02:48:16 PM
Re: Maverick0408 post# 449968 0
Post #
449993
of 450153
I disagree Maverick0408, if Linda Powers and the rest of the NWBio management team, can continue to execute on the following:

(1) successfully navigate through all the challenges and obstacles inherent in completing a multi-national Phase III clinical trial, in 4 different countries (US, UK, Canada, Germany) for 1 of the most difficult to treat diseases in the world, and where dozens of other large & small pharmaceutical companies, who have tried since 2005 have failed;

(2) overcome the torrrent of resistance from legal and illegal shorts, hedge funds, and other who have been actively and aggressively trying to stop NWBio from succeeding;

(3) overcome the barrage of coordinated and concerted disinformation, misinformation and outright lies about NWBio and the DCVax vaccine platform, all across social media, message boards, chat roooms, etc;

(4) finally, release positive DCVax-L TLD and journal article; and

(5) Obtain regulatory approvals for DCVax-L in the US, UK, Canada, Germany and the rest of the EU.

Others may hop off this train after TLD and a nice pop in NWBO share price. There is nothing wrong with that, and that is totally their decision.

I will continue to ride with this management team beyond this first phase of success (regulatory approval in the US, UK, Canada, Germany and the rest of the EU), until the facts on the ground tells me that they have stopped executing their additional business plans (DCVax Direct positive trials & approvals, DCVax-L approvals for other solid tumor cancers, etc.

Thursday, 03/10/22 06:02:32 AM
Re: The Danish Dude post# 450150 0
Post #
450152
of 450154
Thanks DD,L found this interesting:-

Available information on National Phase entries

Israel 13.03.2018 286225 Divisional 09.09.2021

United States of America 13.03.2018 15759699 Published 14.02.2019

Japan 14.03.2018 2018513634

Mexico 14.03.2018 MX/a/2018/003197 Published 19.10.2018

Singapore 14.03.2018 11201802088W

Australia 13.04.2018 2016323066 Published 10.05.2018

Republic of Korea 13.04.2018 1020187010610 Published 02.05.2018

European Patent Office 16.04.2018 2016847253 Published 25.07.2018

Russian Federation 16.04.2018 2018113435 Published 16.10.2019
Granted 16.06.2021

Brazil 26.06.2018 112018005180

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2017048875

Also, In the International Application Status Report you noted published today, includes the following abstract:-

The present disclosure provides partially mature and activated dendritic cells that produce levels of cytokines/chemokines,
for example, one or any combination of, and/or all of IL-6, IL-8, IL-12 and/or TNF#, that are correlated with improved clinical
outcomes, significantly increased survival times and significantly increased times to tumor or cancer recurrence. The determined
threshold amounts of these cytokines can be used for (i) a immunotherapeutic potency test for activated dendritic cells, (ii)
selecting responder patients, (iii) rejecting non-responder patients, and (iv) to screen for dendritic cell activation or maturation
agents that can also induce the production of the threshold amount of the cytokines/chemokines


ATLnsider Thursday, 03/10/22 12:49:29 AM
Re: Poor Man - post# 450127 0
Post #
450130
of 450155
Who has a gun at their head? NWBio has all of the leverage, plus they have an Ace (Flaskworks). I believe that 1 of the main reasons Charles River Laboratories (CRL) bought Cognate is because of the DCVax vaccine platform. DCVax could become SOC to treat solid tumor cancers worldwide. CRL wants to be a part of that.

The updated CDMO agreement will be beneficial to both sides.


ATLnsider Thursday, 03/10/22 01:29:53 AM
Re: barnstormer post# 450134 0
Post #
450141
of 450155
barnstormer, it’s good to hear from you. I respect and understand your opinion. I believe that the peer-review process is either complete, or close to being complete. Also, the peer-review process is journal specific. So, if you start the peer-review process with the NEJM, you would usually wait until the peer-review process is complete with NEJM, and then wait until the NEJM gives you a publication date.

It would be tough to change journals during the pe




ATLnsider Thursday, 03/10/22 12:14:44 AM
Re: Poor Man - post# 450101 0
Post #
450118
of 450155
Poor Man, I don’t understand why you say NWBio is waiting until the last 4 to 6 months to negotiate the CDMO agreement with Cognate / CRL. Please re-read my post again.

(1) The Cognate CDMO agreement is in place, and has been in place since 2014, and it was updated in 2019.

(2) The Cognate CDMO does not expire until 5 years after DCVax-L is approved by the first regulatory authority.

(3) The Cognate CDMO agreement does need to be updated to reflect current DCVax-L production costs, assuming commercialization scale instead of clinical trial scale.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168149835